Miniatura

Fitxers

PIIS1201971224001413.pdf (387.27 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-07-01

Llicència de publicació

cc by-nc-nd (c) Monzó Gallo, Patricia et al, 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/214060

Safety and effectiveness of isavuconazole in real-life non-neutropenic patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ijid.2024.107070

Resum

Objectives: Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life. Methods: A retrospective, observational multicentric study of non-neutropenic patients who received isavuconazole as an IFI treatment at 12 different university hospitals (January 2018-2022). All patients met criteria for proven, probable or possible IFI according to EORTC-MSG. Results: A total of 238 IFIs were treated with isavuconazole during the study period. Combination therapy was administered in 27.7% of cases. The primary IFI was aspergillosis (217, 91.2%). Other IFIs treated with isavuconazole were candidemia (n = 10), mucormycosis (n = 8), histoplasmosis (n = 2), cryptococcosis (n = 2), and others (n = 4). Median time of isavuconazole treatment was 29 days. Only 5.9% (n = 14) of cases developed toxicity, mainly hepatic-related (10 patients, 4.2%). Nine patients (3.8%) had treatment withdrawn. Successful clinical response at 12 weeks was documented in 50.5% of patients. Conclusion: Isavuconazole is an adequate treatment for non-neutropenic patients with IFIs. Toxicity rates were low and its effectiveness was comparable to other antifungal therapies previously reported. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Matèries

Micosi, Medicació oral

Matèries (anglès)

Mycosis, Oral medication

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

MONZÓ GALLO, Patricia, LOPERA, Carlos, BADÍA TEJERO, Ana maría, MACHADO, Marina, GARCÍA RODRÍGUEZ, Julio, VIDAL CORTÉS, Pablo, MERINO CABRERA, Esperanza, CALDERÓN, Jorge, FORTÚN, Jesús, PALACIOS BAENA, Zaira r., PEMÁN, Javier, ROIG SANCHIS, Joan, AGUILAR GUISADO, Manuela, GUDIOL GONZÁLEZ, Carlota, RAMOS, Juan c, SÁNCHEZ ROMERO, Isabel, MARTÍN DAVILA, Pilar, LÓPEZ CORTÉS, Luis e., SALAVERT, Miguel, RUIZ, Isabel (ruiz camps), CHUMBITA, Mariana, AIELLO, Tommaso francesco, PEYRONY, Olivier, PUERTA-ALCALDE, Pedro, SORIANO, Alex, MARCO, Francesc, GARCÍA VIDAL, Carolina. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients. _International Journal of Infectious Diseases_. 2024. Vol. 144. [consulta: 20 de gener de 2026]. ISSN: 1201-9712. [Disponible a: https://hdl.handle.net/2445/214060]

Exportar metadades

JSON - METS

Compartir registre